Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...

The announcement comes just after Dexcom, another diabetes company, released its own consumer-friendly sensor. Here's what to ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Abbott introduced a revolutionary new device, FreeStyle Navigator, designed to improve the lives of the world’s more than 500 million diabetes patients by offering continuous glucose monitoring with ...

The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class ...

The Food and Drug Administration cleared Abbott’s Freestyle Libre 2 and 3 for integration with AID systems in March 2023. Earlier this year, Abbott integrated its FreeStyle Libre 2 Plus sensor with ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Abbott has announced the U.S. availability of Lingo, the company’s first glucose monitoring system available without ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

The episode was not found or is unavailable. In this bonus episode Emma speaks to Dawn Adams, a midwife and menopause ...

Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...